Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: A colostrum-enriched composition comprising at least 0.1 to 12 wt % immunoglobulin (at least 0.1 to 12g per 100 g composition dry weight) isolated from whey.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: Provided is a method for predicting, diagnosing or monitoring an infection or condition caused by or associated with one or more microorganisms in a non-human female animal subject, comprising generating a glycosylation profile from a glycan-containing test sample of the subject, determining from the glycosylation profile one or more test values of one or more glycosylation markers of the infection or condition, comparing the one or more test values of the one or more glycosylation markers to one or more threshold values of the one or more glycosylation markers, and providing a prediction or diagnosis of the infection or condition based on the comparison.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: This invention provides a method of augmenting an epithelial mucosal barrier, by contacting the barrier with a topical composition. This invention also provides the topical composition. The topical composition comprises, dispersed or dissolved in a topically acceptable vehicle, at least one polymer containing either a repeat unit of structure 1 or a repeat unit of structure 2, or a mixture This method and composition are useful in improving mucosal barrier function by, for example, topical application to an exposed or injured epithelial surface or by coating a compromised mucosal barrier in, for example, inflammatory bowel disease.